These antibodies are approved for fewer indications than anti-PD-1 blockers, i.e., mUC, Merkel Cell carcinoma, NSCLC and, in combination with chemotherapy, triple-negative breast cancer and small cell lung cancer, with less reports so far about the predictive role of myeloid cells on the clinical response. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.